Pluristem Therapeutics, Inc. (NASDAQ:PSTI)‘s stock had its “buy” rating reaffirmed by equities research analysts at FBR & Co in a report released on Tuesday.
Other equities research analysts have also issued research reports about the company. Zacks Investment Research upgraded Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 20th. Maxim Group restated a “buy” rating and set a $3.00 price objective on shares of Pluristem Therapeutics in a research note on Monday, September 12th.
Pluristem Therapeutics (NASDAQ:PSTI) traded down 3.889% on Tuesday, hitting $1.557. The stock had a trading volume of 165,986 shares. The company’s market cap is $126.15 million. Pluristem Therapeutics has a 12-month low of $0.71 and a 12-month high of $1.85. The company’s 50 day moving average price is $1.50 and its 200-day moving average price is $1.53.
TRADEMARK VIOLATION WARNING: “FBR & Co Reiterates Buy Rating for Pluristem Therapeutics, Inc. (PSTI)” was first reported by Community Financial News and is the propert of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/01/11/fbr-co-reiterates-buy-rating-for-pluristem-therapeutics-inc-psti.html.
A hedge fund recently raised its stake in Pluristem Therapeutics stock. Oppenheimer & Co. Inc. boosted its position in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 23.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 127,000 shares of the company’s stock after buying an additional 24,000 shares during the period. Oppenheimer & Co. Inc. owned 0.16% of Pluristem Therapeutics worth $203,000 as of its most recent filing with the SEC. 3.55% of the stock is currently owned by institutional investors and hedge funds.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
What are top analysts saying about Pluristem Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pluristem Therapeutics Inc. and related companies.